Blue Spark Technologies to Highlight Continuous Patient Temperature Monitoring at CES 2023
Blue Spark Technologies, Inc., a leader in wearable remote patient monitoring solutions, will showcase TempTraq® at the 2023 Consumer Electronics Show (CES) at the Las Vegas Convention Center January 5-8. The remote patient monitoring company plans to demonstrate its continuous temperature monitoring device as part of the Medidata Sensor Cloud exhibit. Built within the Medidata unified data platform, Sensor Cloud manages a broad range of wearable sensor and digital health technology data for clinical trials. Medidata is one of the features of the Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA) presence at CES, which is located at booth number 8705 in the digital healthcare pavilion.
Blue Spark Technologies Announces Appointment of John DeFord, Ph.D. to its Board of Directors
Blue Spark Technologies Inc., a leader in wearable remote patient monitoring solutions, announced today the appointment of John DeFord, Ph.D. to its board of directors. Dr. DeFord’s appointment, effective April 13th, 2022, brings the number of board members to five.
Blue Spark Technologies Raises $40 Million in Growth Funding Led by Ghost Tree Partners to Advance AI-Based Remote Patient Monitoring
Blue Spark Technologies, Inc., a leader in wearable remote patient monitoring solutions, today announced that it has raised a $40 million intellectual property-based debt solution to fund growth led by GT Investment Partners (“Ghost Tree Partners”) with support from Aon plc (
NYSEAON). The funding will go towards scaling the company’s sales and marketing functions and the continued advancement of Blue Spark’s wearable remote patient monitoring solutions.
Blue Spark Technologies Announces Observational Trial Using TempTraq® Wearable Device in CAR T Patient Monitoring
Blue Spark Technologies, Inc. today announced that Bristol Myers Squibb (BMS, NYSE: BMY) will use its TempTraq wearable Bluetooth continuous body temperature monitoring platform in a U.S. observational trial to monitor patients across multiple BMS CAR T assets prior to and following CAR T patients’ infusion with the cell therapy. This observational trial will be Bristol Myers Squibb’s first use of a remote patient monitoring technology to track CAR T patient temperatures, which can be a sign of cytokine release syndrome (CRS), a common side effect observed within the CAR T category of therapies.
